Vaccine manufacturing major Serum Institute of India (SII) on Monday said it’s applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its COVID-19 vaccine Covishield.
The Pune-based company has collaborated with Oxford University and drug company Astra Zeneca for creating the vaccine and is conducting trials in India.
“As promised, before the top of 2020, @SerumInstIndia has applied for emergency use authorisation for the primary made-in-India vaccine, Covishield,” SII CEO Adar Poonawala said during a tweet.
He further said: “This will save countless lives, and that i thank the govt of India and Sri @narendramodi ji for his or her invaluable support.”
Last week, Pfizer India said it’s applied to India’s drug regulator DCGI for emergency-use authorisation for its COVID-19 vaccine, after the company’s parent received clearance for the treatment from Britain and Bahrain.
